MorphoSys Takes MOR202 Back From Celgene, Will Seek New Partner
This article was originally published in The Pink Sheet Daily
MorphoSys is putting on a brave face after Celgene handed back rights to its anti-CD38 monoclonal antibody MOR202, saying it will carry on with current trials in multiple myeloma patients and voicing confidence it can find another commercial partner “once the time is right.”
You may also be interested in...
MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans
MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Janssen Boosts Multiple Myeloma R&D With Genmab Deal
Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.